SCHEMBL12000720

SCHEMBL12000720

Cc1ccc(N(c2ccccc2)c2ccc(-c3cccc([Si](c4ccccc4)(c4ccccc4)c4cccc(-c5ccc(N(c6ccc(C)cc6)c6ccc(C)cc6)cc5)c4)c3)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TDP1 Q9NUW8 3/20 0.37
HPGD P15428 2/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPT P10636 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
FLT3 P36888 1/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
NFKB1 P19838 2/20 0.37
NFKB2 Q00653 2/20 0.37
RELA Q04206 2/20 0.37
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CASP3 P42574 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12000722 0.98 MEN1 (0.39) MEN1KMT2ATDP1HPGDKDM4E
SCHEMBL12000719 0.94 APP (0.35) MEN1KMT2ATDP1HPGDKDM4E
SCHEMBL16843025 0.92 PTPN5 (0.39) MEN1KMT2ATDP1HPGDKDM4E
SCHEMBL17118567 0.91 MGLL (0.37) MEN1KMT2ATDP1HPGDKDM4E
SCHEMBL21365232 0.91 MGLL (0.37) MEN1KMT2ATDP1HPGDKDM4E
SCHEMBL21365231 0.89 ALDH1A1 (0.37) MEN1KMT2ATDP1KDM4EALDH1A1
SCHEMBL12721627 0.89 ALDH1A1 (0.39) MEN1KMT2ATDP1HPGDKDM4E
SCHEMBL16843031 0.89 ALDH1A1 (0.39) MEN1KMT2ATDP1HPGDKDM4E
SCHEMBL12721582 0.89 ALDH1A1 (0.39) MEN1KMT2ATDP1HPGDKDM4E
SCHEMBL17118575 0.89 NPC1 (0.42) MEN1KMT2ATDP1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9343684-B2 Substituted bisaryloxybiphenyl compounds for use in light-emitting devices NITTO DENKO CORPORATION (JP) 2016-05-17 US disclosed
US-9343684-B2 Substituted bisaryloxybiphenyl compounds for use in light-emitting devices NITTO DENKO CORPORATION (JP) 2016-05-17 US disclosed
US-20140284554-A1 SUBSTITUTED BISARYLOXYBIPHENYL COMPOUNDS FOR USE IN LIGHT-EMITTING DEVICES NITTO DENKO CORPORATION (JP) 2014-09-25 US disclosed
US-20140284554-A1 SUBSTITUTED BISARYLOXYBIPHENYL COMPOUNDS FOR USE IN LIGHT-EMITTING DEVICES NITTO DENKO CORPORATION (JP) 2014-09-25 US disclosed
US-20120214269-A1 TETRAPHENYLSILANE COMPOUNDS SUITABLE AS ORGANIC HOLE-TRANSPORT MATERIALS NITTO DENKO CORPORATION (JP) 2012-08-23 US disclosed
US-20120214269-A1 TETRAPHENYLSILANE COMPOUNDS SUITABLE AS ORGANIC HOLE-TRANSPORT MATERIALS NITTO DENKO CORPORATION (JP) 2012-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214269-A1 TETRAPHENYLSILANE COMPOUNDS SUITABLE AS ORGANIC HOLE-TRANSPORT MATERIALS PAH, SLC7A5, SLCO2A1 MEN1 225/4885KMT2A 804/4885TDP1 2329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.